Earnings Call Summary | Alpha Teknova(TKNO.US) Q4 2023 Earnings Conference
Earnings Call Summary | Alpha Teknova(TKNO.US) Q4 2023 Earnings Conference
The following is a summary of the Alpha Teknova, Inc. (TKNO) Q4 2023 Earnings Call Transcript:
以下是Alpha Teknova, Inc.（TKNO）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Alpha Teknova reported a flat Q4 revenue of $7.9 million compared to Q4 2022, and an 11% decrease in annual revenue to $36.7 million from 2022.
Gross profit for Q4 2023 dropped to $1.3 million from $2.1 million in Q4 2022, and yearly gross profit decreased to $10.3 million from $17.5 million in 2022. Gross margin percentage also saw a decrease from 26.7% in Q4 2022 to 17.0% in Q4 2023.
Net loss improved from a loss of $13.3 million in Q4 2022 to $10.7 million in Q4 2023. For the full year, net loss decreased from $47.5 million in 2022 to $36.8m in 2023.
The company achieved a reduction in operating expenses and capital expenditures, alongside increased savings from a reduction in headcount. It aims to achieve positive adjusted EBITDA and free cash flow by 2025.
2024 revenue is expected to remain relatively flat at $35-38 million.
Alpha Teknova報告稱，與2022年第四季度相比，第四季度收入持平至790萬美元，年收入比2022年下降11％，至3,670萬美元。
2023年第四季度的毛利從2022年第四季度的210萬美元降至130萬美元，年毛利從2022年的1,750萬美元降至1,030萬美元。毛利率百分比也從2022年第四季度的26.7％下降到2023年第四季度的17.0％。
淨虧損從2022年第四季度的1,330萬美元虧損增加到2023年第四季度的1,070萬美元。全年淨虧損從2022年的4,750萬美元下降到2023年的3680萬美元。
該公司減少了運營費用和資本支出，同時通過裁員增加了儲蓄。其目標是到2025年實現調整後的息稅折舊攤銷前利潤和自由現金流。
預計2024年的收入將保持相對平穩，爲3500萬至3800萬美元。
Business Progress:
業務進展：
The company successfully expanded its customer base in the Clinical Solutions segment and delivered new initiatives in product innovation and efficiency, particularly in the Lab Essentials category.
Measures to increase production efficiency led to achieved savings of over $8 million annually, with adjusted EBITDA breakeven revenue dropping to $50-55 million.
The company plans to aggressively manage expenses while continuing to onboard new target customers, despite expecting modest revenue growth in 2024.
Alpha Teknova remains optimistic about long-term prospects due to a positive outlook for end markets and will continue its focus on aiding clients in introducing new therapies, diagnostics, and products to improve human health.
該公司成功擴大了臨床解決方案領域的客戶群，並在產品創新和效率方面推出了新的舉措，尤其是在實驗室必備品類別。
提高生產效率的措施使每年節省超過800萬美元，調整後的息稅折舊攤銷前利潤盈虧平衡收入降至5000萬至5500萬美元。
儘管預計2024年收入將略有增長，但該公司仍計劃積極管理開支，同時繼續吸引新的目標客戶。
由於終端市場前景樂觀，Alpha Teknova對長期前景仍然持樂觀態度，並將繼續專注於幫助客戶推出新的療法、診斷和產品以改善人類健康。
More details: Alpha Teknova IR
更多詳情： 阿爾法 Teknova 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。